Seattle Genetics Inc Discussion of Oncology Collaborations with Merck & Co Inc - Conference Call Transcript
Good day, everyone. And welcome to the Seattle Genetics conference call to discuss its oncology collaborations with Merck. (Operator Instructions) Please also note today's event is being recorded. And at this time, I'd like to turn the conference call over to Ms. Peggy Pinkston, Vice President of Investor Relations. Ma'am, please go ahead.
Thank you, operator, and good morning, everyone. I'm pleased to welcome you to today's conference call to discuss the joint announcement with Merck this morning regarding our collaborations on ladiratuzumab vedotin and TUKYSA.
I'm joined today by Clay Siegall, President and Chief Executive Officer; Todd Simpson, Chief Financial Officer; and Roger Dansey, Chief Medical Officer. Following Clay's prepared remarks, we'll open the line for your questions.
Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the anticipated closing of Merck
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |